Senator Bernie Sanders dropped his subpoena pursuit against Novo Nordisk's executive after the company's CEO agreed to testify voluntarily before the Senate on the high costs of their medications in the U.S. Click here for article.
Subpoena Withdrawal: Sanders canceled a planned subpoena vote after Novo Nordisk's CEO agreed to testify voluntarily.
Testimony Agreement: CEO Lars Fruergaard Jørgensen will appear before the Senate HELP Committee in early September.
Investigation Focus: The hearing will investigate the pricing disparities of Novo Nordisk's semaglutide products (Ozempic and Wegovy) between the U.S. and other countries.
Political Context: The move is seen as a tactic to highlight and address high drug costs amidst ongoing political pressure on pharmaceutical pricing.
Comments